BI 425809

Drug Profile

BI 425809

Alternative Names: BI-425809

Latest Information Update: 18 Oct 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antidementias
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cognition disorders

Most Recent Events

  • 10 Mar 2017 Boehringer Ingelheim plans a phase I trial in Healthy volunteers in Germany (NCT03082183)
  • 03 Oct 2016 Boehringer Ingelheim suspends enrolment in a phase II trial for Cognition disorders (in patients with Schizophrenia) in Austria, Poland, Spain, USA, Japan, Canada, United Kingdom, Italy, Germany, South Korea and Taiwan (PO) (NCT02832037)
  • 03 Oct 2016 Boehringer Ingelheim suspends enrolment in a phase II trial for Cognition disorders (in patients with Alzheimer's disease) in Finland, Norway, USA, Austria, Hungary, Canada, France, United Kingdom, Italy, Japan, Spain, Greece and Germany (PO) (NCT02788513)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top